NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, TO US PERSONS OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

THE COMMUNICATION OF THIS ANNOUNCEMENT AND ANY OTHER DOCUMENTS OR MATERIALS RELATING TO THE RETAIL OFFER AS A FINANCIAL PROMOTION IS ONLY BEING MADE TO, AND MAY ONLY BE ACTED UPON BY, THOSE PERSONS IN THE UNITED KINGDOM FALLING WITHIN ARTICLE 43 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (WHICH INCLUDES AN EXISTING MEMBER OF CELLBXHEALTH PLC). ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO SUCH PERSONS AND WILL BE ENGAGED IN ONLY BY SUCH PERSONS. THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY, AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES OF CELLBXHEALTH PLC.

The Board of CELLBXHEALTH plc (the "Company") (AIM: CLBX), a leader in circulating tumour cell (CTC) intelligence, is pleased to announce that the Retail Offer launched on 25 November 2025 has now closed, raising gross proceeds of approximately £0.96 million. Subject to the Retail Offer becoming unconditional, a total of 95,869,449 Retail Offer Shares will be issued at a price of 1.0 pence each.

As set out in the circular published on 25 November 2025, the issue of the Retail Offer Shares is conditional upon the Resolutions being duly passed without amendment at the General Meeting to be held on 15 December 2025.

Following the close of the Retail Offer, the Company has conditionally raised, in aggregate, gross proceeds of approximately £7.8 million at the Issue Price via the Fundraising.  Subject to the passing of the Resolutions at the General Meeting, the Company will issue and allot a total of 775,869,449 New Ordinary Shares. The issued share capital of the Company following Admission (including the New Ordinary Shares) (the "Enlarged Share Capital") will be a total of 1,098,511,117 New Ordinary Shares.

Subject to the passing of the Resolutions, First Admission of 9,090,000 First Tranche Fundraising Shares is expected to occur at 8.00 a.m. on or around 16 December 2025.   Second Admission will be in respect of 766,779,449 Second Tranche Placing Shares, the Subscription Shares and the Retail Offer Shares and is expected to occur at 8.00 a.m. on 18 December 2025 (or, in each case, such later time and/or date as the Company and Cavendish may agree (being no later than 8.00 a.m. on 16 January 2026)).

A separate announcement will be made following the General Meeting of the results of the General Meeting and the total voting rights following Admission.

Cavendish Capital Markets Limited ("Cavendish") acted as Nominated Adviser, Broker and Bookrunner in connection with the Fundraising.

Unless otherwise defined, all capitalised terms used but not defined in this announcement shall have the meaning given to them in the announcement of the Fundraising made by the Company on 24 November 2025.

Geoff Nash / Isaac Hooper/ Hamza Munshi (Corporate Finance)

CelLBxHealth plc is a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows.